Metabotropic glutamate receptor 1 acts as a dependence receptor creating a requirement for glutamate to sustain the viability and growth of human melanomas (original) (raw)

• American Cancer Society Cancer Facts & Figures 2013. American Cancer Society: Atlant, GA, USA, 2013.
• Yajima I, Kumasaka MY, Thang ND, Goto Y, Takeda K, Yamanoshita O et al. RAS/RAF/MEK/ERK and PI3K/PTEN/AKT signaling in malignant melanoma progression and therapy. Dermatol Res Pract 2012; 2012: 1–5.
  Article Google Scholar
• Maira F, Catania A, Candido S, Russo AE, McCubrey JA, Libra M et al. Molecular targeted therapy in melanoma: a way to reverse resistance to conventional drugs. Curr Drug Deliv 2012; 9: 17–29.
  Article CAS Google Scholar
• Namkoong J, Shin SS, Lee HJ, Marín YE, Wall BA, Goydos JS et al. Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res 2007; 67: 2298–2305.
  Article CAS Google Scholar
• Pollock PM, Cohen-Solal K, Sood R, Namkoong J, Martino JJ, Koganti A et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet 2003; 34: 108–112.
  Article CAS Google Scholar
• Shin SS, Namkoong J, Wall BA, Gleason R, Lee HJ, Chen S . Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation. Pigment Cell Melanoma Res 2008; 21: 368–378.
  Article CAS PubMed Central Google Scholar
• Khan AJ, Wall B, Ahlawat S, Green C, Schiff D, Mehnert JM et al. Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo. Clin Cancer Res 2011; 17: 1807–1814.
  Article CAS PubMed Central Google Scholar
• Shin SS, Martino JJ, Chen S . Metabotropic glutamate receptors (mGluRs) and cellular transformation. Neuropharmacology 2008; 55: 396–402.
  Article CAS PubMed Central Google Scholar
• Wangari-Talbot J, Wall BA, Goydos JS, Chen S . Functional effects of GRM1 suppression in human melanoma cells. Mol Cancer Res 2012; 10: 1440–1450.
  Article CAS PubMed Central Google Scholar
• Ohtani Y, Harada T, Funasaka Y, Nakao K, Takahara C, Abdel-Daim M et al. Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma. Oncogene 2008; 27: 7162–7170.
  Article CAS Google Scholar
• Le MN, Chan JL, Rosenberg SA, Nabatian AS, Merrigan KT, Cohen-Solal KA et al. The glutamate release inhibitor riluzole decreases migration, invasion, and proliferation of melanoma cells. J Invest Dermatol 2010; 130: 2240–2249.
  Article CAS PubMed Central Google Scholar
• Conn PJ, Pin JP . Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997; 37: 205–237.
  Article CAS Google Scholar
• Pin JP, Duvoisin R . The metabotropic glutamate receptors: structure and functions. Neuropharmacology 1995; 34: 1–26.
  Article CAS Google Scholar
• Teh J, Chen S . Metabotropic glutamate receptors and cancerous growth. Wiley Interdiscip Rev Membr Transp Signal 2012; 1: 211–220.
  Article CAS Google Scholar
• Speyer CL, Smith JS, Banda M, DeVries JA, Mekani T, Gorski DH . Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer. Breast Cancer Res Treat 2012; 132: 565–573.
  Article CAS Google Scholar
• Banda M, Speyer CL, Semma SN, Osuala KO, Kounalakis N, Torres KE et al. Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer. PLoS ONE 2014; 9: 1–12.
  Article Google Scholar
• Chang HJ, Yoo BC, Lim SB, Jeong SY, Kim WH, Park JG . Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance. Clin Cancer Res 2005; 11: 3288–3295.
  Article CAS Google Scholar
• Brocke KS, Staufner C, Luksch H, Geiger KD, Stepulak A, Marzahn J et al. Glutamate receptors in pediatric tumors of the central nervous system. Cancer Biol Ther 2010; 9: 455–468.
  Article CAS Google Scholar
• Park SY, Lee SA, Han IH, Yoo BC, Lee SH, Park JY et al. Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma. Oncol Rep 2007; 17: 81–87.
  PubMed Google Scholar
• de Groot J, Sontheimer H . Glutamate and the biology of gliomas. Glia 2011; 59: 1181–1189.
  Article Google Scholar
• Ye ZC, Sontheimer H . Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 1999; 59: 4383–4391.
  CAS PubMed Google Scholar
• Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H . Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res 2007; 67: 9463–9471.
  Article CAS PubMed Central Google Scholar
• Lee HJ, Wall BA, Wangari-Talbot J, Shin SS, Rosenberg S, Chan JL et al. Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies. Clin Cancer Res 2011; 17: 7080–7092.
  Article CAS PubMed Central Google Scholar
• Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468: 968–972.
  Article CAS PubMed Central Google Scholar
• DiRaddo JO, Pshenichkin S, Gelb T, Wroblewski JT . Two newly identified exons in human GRM1 express a novel splice variant of metabotropic glutamate 1 receptor. Gene 2013; 519: 367–373.
  Article CAS PubMed Central Google Scholar
• Lee HJ, Wall BA, Wangari-Talbot J, Chen S . Regulation of mGluR1 expression in human melanocytes and melanoma cells. BBA Gene Regulatory Mechanisms 2012; 1819: 1123–1131.
  CAS PubMed Google Scholar
• Frati C, Marchese C, Fisichella G, Copani A, Nasca MR, Storto M et al. Expression of functional mGlu5 metabotropic glutamate receptors in human melanocytes. J Cell Physiol 2000; 183: 364–372.
  Article CAS Google Scholar
• Wen Y, Li J, Koo J, Shin SS, Lin Y, Jeong BS et al. Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression. Cancer Res. 2014; 74: 2499–2509.
  Article CAS PubMed Central Google Scholar
• Deng W, Yue Q, Rosenberg PA, Volpe JJ, Jensen FE . Oligodendrocyte excitotoxicity determined by local glutamate accumulation and mitochondrial function. J Neurochem 2006; 98: 213–222.
  Article CAS Google Scholar
• Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P et al. Features of apoptotic cells measured by flow cytometry. Cytometry 1992; 13: 795–808.
  Article CAS Google Scholar
• Ringer L, Sirajuddin P, Heckler M, Ghosh A, Suprynowicz F, Yenugonda VM et al. VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells. Cancer Biol Ther 2011; 12: 818–826.
  Article CAS PubMed Central Google Scholar
• Lavreysen H, Wouters R, Bischoff F, Nóbrega Pereira S, Langlois X, Blokland S et al. JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist. Neuropharmacology 2004; 47: 961–972.
  Article CAS Google Scholar
• Prickett TD, Samuels Y . Molecular pathways: dysregulated glutamatergic signaling pathways in cancer. Clin Cancer Res 2012; 18: 4240–4246.
  Article CAS PubMed Central Google Scholar
• Willard SS, Koochekpour S . Glutamate, glutamate receptors, and downstream signaling pathways. Int J Biol Sci 2013; 9: 948–959.
  Article CAS PubMed Central Google Scholar
• Seidlitz EP, Sharma MK, Saikali Z, Ghert M, Singh G . Cancer cell lines release glutamate into the extracellular environment. Clin Exp Metastasis 2009; 26: 781–787.
  Article CAS Google Scholar
• Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M . Glutamate release promotes growth of malignant gliomas. Nat Med 2001; 7: 1010–1015.
  Article CAS Google Scholar
• Koochekpour S, Majumdar S, Azabdaftari G, Attwood K, Scioneaux R, Subramani D et al. Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells. Clin Cancer Res 2012; 18: 5888–5901.
  Article CAS PubMed Central Google Scholar
• Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 2011; 43: 442–446.
  Article CAS PubMed Central Google Scholar
• Ortiz P, Vanaclocha F, López-Bran E, Esquivias JI, López-Estebaranz JL, Martín-González M et al. Genetic analysis of the GRM1 gene in human melanoma susceptibility. Eur J Hum Genet 2007; 15: 1176–1182.
  Article CAS Google Scholar
• Steckler T, Lavreysen H, Oliveira AM, Aerts N, Van Craenendonck H, Prickaerts J et al. Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test. Psychopharmacology (Berl) 2005; 179: 198–206.
  Article CAS Google Scholar
• Steckler T, Oliveira AF, Van Dyck C, Van Craenendonck H, Mateus AM, Langlois X et al. Metabotropic glutamate receptor 1 blockade impairs acquisition and retention in a spatial Water maze task. Behav Brain Res 2005; 14: 52–60.
  Article Google Scholar
• Pshenichkin S, Dolińska M, Klauzińska M, Luchenko V, Grajkowska E, Wroblewski JT . Dual neurotoxic and neuroprotective role of metabotropic glutamate receptor 1 in conditions of trophic deprivation—possible role as a dependence receptor. Neuropharmacology 2008; 55: 500–508.
  Article CAS PubMed Central Google Scholar
• Goldschneider D, Mehlen P . Dependence receptors: a new paradigm in cell signaling and cancer therapy. Oncogene 2010; 29: 1865–1882.
  Article CAS Google Scholar
• Fitamant J, Guenebeaud C, Coissieux MM, Guix C, Treilleux I, Scoazec JY et al. Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. Proc Natl Acad Sci USA 2008; 105: 4850–4855.
  Article CAS Google Scholar
• Delloye-Bourgeois C, Brambilla E, Coissieux MM, Guenebeaud C, Pedeux R, Firlej V et al. Interference with netrin-1 and tumor cell death in non-small cell lung cancer. J Natl Cancer Inst 2009; 101: 237–247.
  Article CAS Google Scholar
• Delloye-Bourgeois C, Fitamant J, Paradisi A, Cappellen D, Douc-Rasy S, Raquin MA et al. Netrin-1 acts as a survival factor for aggressive neuroblastoma. J Exp Med 2009; 206: 833–847.
  Article CAS PubMed Central Google Scholar
• Rzeski W, Ikonomidou C, Turski L . Glutamate antagonists limit tumor growth. Biochem Pharmacol 2002; 98: 1195–1200.
  Article Google Scholar
• Blaabjerg M, Fang L, Zimmer J, Baskys A . Neuroprotection against NMDA excitotoxicity by group I metabotropic glutamate receptors is associated with reduction of NMDA stimulated currents. Exp Neurol 2003; 183: 573–580.
  Article CAS Google Scholar
• Hoogduijn MJ, Hitchcock IS, Smit NP, Gillbro JM, Schallreuter KU, Genever PG . Glutamate receptors on human melanocytes regulate the expression of MiTF. Pigment Cell Res 2006; 19: 58–67.
  Article CAS Google Scholar
• Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. New Engl J Med 2012; 367: 1694–1703.
  Article CAS Google Scholar
• Emery AC, Pshenichkin S, Takoudjou GR, Grajkowska E, Wolfe BB, Wroblewski JT et al. The protective signaling of metabotropic glutamate receptor 1 is mediated by sustained, beta-arrestin-1-dependent ERK phosphorylation. J Biol Chem 2010; 285: 26041–26048.
  Article CAS PubMed Central Google Scholar
• Edward HJ, Kevin Basile K, Aplin AE . Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma. Mol Cancer Res 2014; 12: 795–802.
  Article Google Scholar
• Martino JJ, Wall BA, Mastrantoni E, Wilimczyk BJ, La Cava SN, Degenhardt K et al. Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells. Oncogene 2013; 32: 4366–4376.
  Article CAS Google Scholar